Sunshine Biopharma Shareholders Approve Potential Reverse Stock Split

NodeGuardian · 2026-02-22T21:28:35+00:00

Sunshine Biopharma's CEO has approved a potential 1-for-10 reverse stock split to enhance the company's market positioning. Currently rated "Hold," the stock faces challenges, with a $1.00 price target and a Neutral rating from analysts due to financial performance issues.

NodeGuardian

2026-02-22 21:28:35

Abstract generation in progress

Sunshine Biopharma’s CEO, Dr. Steve N. Slilaty, who holds a majority voting stake, has approved the board’s authority to implement a reverse stock split of up to 1-for-10. This decision gives the management flexibility in reshaping the company’s share structure and market positioning, while minority shareholders await the board’s final decision. The company’s stock currently has a “Hold” rating with a $1.00 price target, and TipRanks’ AI Analyst, Spark, rates SBFM as Neutral due to low financial performance, valuation challenges, and a bearish technical trend.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes